| pubmed-article:21533288 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21533288 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:21533288 | lifeskim:mentions | umls-concept:C0029456 | lld:lifeskim |
| pubmed-article:21533288 | lifeskim:mentions | umls-concept:C0012544 | lld:lifeskim |
| pubmed-article:21533288 | lifeskim:mentions | umls-concept:C1548437 | lld:lifeskim |
| pubmed-article:21533288 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21533288 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21533288 | pubmed:dateCreated | 2011-5-2 | lld:pubmed |
| pubmed-article:21533288 | pubmed:abstractText | Despite access to effective, safe, and affordable treatment for osteoporosis, at-risk women may choose not to start bisphosphonate therapy. Understanding the reasons women give for rejecting a clinician's offer of treatment during consultations and how clinician's react to these reasons may help clinicians develop more effective strategies for fracture prevention and medication adherence. | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21533288 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21533288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21533288 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21533288 | pubmed:issn | 1932-6203 | lld:pubmed |
| pubmed-article:21533288 | pubmed:author | pubmed-author:ShahNilay DND | lld:pubmed |
| pubmed-article:21533288 | pubmed:author | pubmed-author:MontoriVictor... | lld:pubmed |
| pubmed-article:21533288 | pubmed:author | pubmed-author:ScovilleEliza... | lld:pubmed |
| pubmed-article:21533288 | pubmed:author | pubmed-author:PencilleLauri... | lld:pubmed |
| pubmed-article:21533288 | pubmed:author | pubmed-author:Ponce de... | lld:pubmed |
| pubmed-article:21533288 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21533288 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:21533288 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21533288 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21533288 | pubmed:pagination | e18468 | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:meshHeading | pubmed-meshheading:21533288... | lld:pubmed |
| pubmed-article:21533288 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21533288 | pubmed:articleTitle | Why do women reject bisphosphonates for osteoporosis? A videographic study. | lld:pubmed |
| pubmed-article:21533288 | pubmed:affiliation | Mayo Medical School, Rochester, Minnesota, United States of America. | lld:pubmed |
| pubmed-article:21533288 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21533288 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21533288 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
